高敏肌钙蛋白早期排除心肌梗死:阶梯楔形整群随机试验
实施就诊时高敏肌钙蛋白I<5 ng/L即排除心梗的早期路径后,住院时间从10.1小时降至6.8小时,出院比例从50%升至71%;30天安全终点非劣效未达统计学标准,但1年心脏事件无增加。
要点
- 就诊时高敏肌钙蛋白I<5 ng/L可安全早期排除心梗并缩短住院时间。
- 实施早期排除路径后出院比例从50%提高至71%。
- 30天安全终点非劣效未达统计学标准,但1年心脏事件无差异。
核心结论
- 实施就诊时高敏肌钙蛋白I<5 ng/L排除心梗的早期路径可缩短住院时间并提高出院比例。
- 30天安全终点非劣效未达统计学标准,但1年心脏事件、再就诊及全因死亡无差异。
研究设计与样本
- 在苏格兰7家急诊医院开展的阶梯楔形整群随机对照试验,纳入2014年12月至2016年12月连续就诊的疑似急性冠脉综合征患者。
- 干预为就诊时高敏肌钙蛋白I<5 ng/L即排除心梗的早期路径,对照为症状发作后6至12小时肌钙蛋白低于第99百分位排除心梗。
- 共同主要终点为住院时间(有效性)和出院后30天内心梗或心源性死亡(安全性),随访1年评估安全性及其他次要终点。
主要发现
- 住院时间从10.1±4.1小时降至6.8±3.9小时(校正几何均值比0.78,95%CI 0.73-0.83,P<0.001)。
- 出院患者比例从50%提高至71%(校正比值比1.59,95%CI 1.45-1.75)。
关键数值与推荐
- 早期排除路径:就诊时高敏肌钙蛋白I浓度<5 ng/L即排除心肌梗死。
- 对照路径:症状发作后6至12小时肌钙蛋白浓度低于第99百分位即排除心肌梗死。
临床怎么用
- 对疑似急性冠脉综合征患者,可考虑采用就诊时高敏肌钙蛋白I<5 ng/L的早期排除路径以缩短住院时间、提高出院比例。
- 应用该路径时需关注30天安全终点非劣效未达统计学标准,尽管1年心脏事件无增加。
局限性
- 30天安全终点非劣效未达统计学标准(P=0.068)。
- 研究在苏格兰7家医院开展,外推需考虑医疗体系差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-sensitivity cardiac troponin assays enable myocardial infarction to be ruled out earlier, but the safety and efficacy of this approach is uncertain. We investigated whether an early rule-out pathway is safe and effective for patients with suspected acute coronary syndrome. METHODS: We performed a stepped-wedge cluster randomized controlled trial in the emergency departments of 7 acute care hospitals in Scotland. Consecutive patients presenting with suspected acute coronary syndrome between December 2014 and December 2016 were included. Sites were randomized to implement an early rule-out pathway where myocardial infarction was excluded if high-sensitivity cardiac troponin I concentrations were <5 ng/L at presentation. During a previous validation phase, myocardial infarction was ruled out when troponin concentrations were <99th percentile at 6 to 12 hours after symptom onset. The coprimary outcome was length of stay (efficacy) and myocardial infarction or cardiac death after discharge at 30 days (safety). Patients were followed for 1 year to evaluate safety and other secondary outcomes. RESULTS: We enrolled 31 492 patients (59±17 years of age [mean±SD]; 45% women) with troponin concentrations <99th percentile at presentation. Length of stay was reduced from 10.1±4.1 to 6.8±3.9 hours (adjusted geometric mean ratio, 0.78 [95% CI, 0.73-0.83]; P<0.001) after implementation and the proportion of patients discharged increased from 50% to 71% (adjusted odds ratio, 1.59 [95% CI, 1.45-1.75]). Noninferiority was not demonstrated for the 30-day safety outcome (upper limit of 1-sided 95% CI for adjusted risk difference, 0.70% [noninferiority margin 0.50%]; P=0.068), but the observed differences favored the early rule-out pathway (0.4% [57/14 700] versus 0.3% [56/16 792]). At 1 year, the safety outcome occurred in 2.7% (396/14 700) and 1.8% (307/16 792) of patients before and after implementation (adjusted odds ratio, 1.02 [95% CI, 0.74-1.40]; P=0.894), and there were no differences in hospital reattendance or all-cause mortality. CONCLUSIONS: Implementation of an early rule-out pathway for myocardial infarction reduced length of stay and hospital admission. Although noninferiority for the safety outcome was not demonstrated at 30 days, there was no increase in cardiac events at 1 year. Adoption of this pathway would have major benefits for patients and health care providers. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03005158.
引用
- Anand A, Lee KK, Chapman AR, et al. High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. Circulation. 2021. PMID: 33752439. doi:10.1161/CIRCULATIONAHA.120.052380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。